.infobox .infobox-protein
!!! Info
- Protein Name: Fibroblast Growth Factor 2 (Basic FGF)
- Gene: FGF2
- UniProt: P09038
- PDB: 1bas, 2bfu, 4oee
- Molecular Weight: 17.2-18.0 kDa
- Subcellular Localization: Extracellular, Nucleus (internalization)
- Protein Family: FGF family, Heparin-binding growth factor
FGF2 (Fibroblast Growth Factor 2), also known as basic FGF (bFGF), is a member of the fibroblast growth factor family that plays critical roles in neuronal survival, development, and repair[1][2]. As a potent neurotrophic factor, FGF2 promotes neuronal survival, modulates neurogenesis, and exerts neuroprotective effects in models of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and stroke[2:1][3][4]. The protein's ability to promote neurogenesis, support synaptic plasticity, and protect against various forms of neuronal injury has made it a focus of extensive research for neurodegenerative disease therapeutics.
FGF2 is a 155-amino acid protein with a molecular weight of approximately 17-18 kDa[1:1][2:2]. The protein lacks a classical signal peptide but is secreted through unconventional secretory pathways. Multiple isoforms exist due to alternative translation initiation from different start codons, generating proteins ranging from 18-34 kDa[1:2][2:3].
The crystal structure of FGF2 reveals a characteristic beta-trefoil fold[1:3]:
The heparin-binding domain is essential for:
FGF2 signals through four main FGFRs (FGFR1-4), with FGFR1 being the primary receptor in neural tissue[1:6][2:5][3:1]:
| Receptor | Expression in Brain | Primary Role |
|---|---|---|
| FGFR1 | Neurons, glia | Major FGF2 receptor in CNS |
| FGFR2 | Limited | Developmental expression |
| FGFR3 | Astrocytes | Glial modulation |
| FGFR4 | Lower levels | Minor role in CNS |
FGF2 binding to FGFR triggers multiple downstream signaling cascades[1:7][2:6][3:2]:
During CNS development, FGF2 plays essential roles[1:9][2:8]:
In the adult brain, FGF2 continues to play important roles[2:10][3:3]:
FGF2 exhibits broad neuroprotective properties[2:12][3:5][4:1]:
FGF2 has complex and multifaceted roles in AD pathophysiology[2:14][3:7][5]:
Neuroprotective effects:
Compensatory upregulation:
Therapeutic challenges:
FGF2 provides neuroprotection in PD models through several mechanisms[3:9][4:3][6]:
Research shows that FGF2 delivery through viral vectors or protein administration improves motor function in PD models[3:10][4:4][6:1].
In ALS, FGF2 shows both protective and disease-modifying effects[3:11][4:5][7]:
Clinical trials have explored FGF2 delivery in ALS, though results have been mixed due to delivery challenges and the complex nature of ALS pathogenesis[3:12][4:6].
FGF2 is one of the most extensively studied neuroprotective factors in stroke[3:13][4:7][8]:
FGF2 has been investigated in clinical trials for acute stroke, though optimal delivery and timing protocols remain under development[3:14][8:1].
FGF2 protein can be delivered through various routes[2:17][3:15][4:8]:
Viral vector-mediated FGF2 delivery has been tested in preclinical models[3:16][4:9]:
FGF2 shows synergy with other neuroprotective approaches[2:18][3:17][4:10]:
The FGF family includes 22 ligands that signal through four FGFRs[1:11][2:19]:
| FGF | Alternative Name | Neurodegeneration Role |
|---|---|---|
| FGF2 (FGF-2) | bFGF | Major neurotrophic factor |
| FGF9 | Neurturin | Supports dopaminergic neurons |
| FGF18 | FGF-18 | Promotes neurogenesis |
| FGF21 | FGF-21 | Metabolic neuroprotection |
Dysregulated FGF signaling is implicated in multiple neurodegenerative conditions[2:20][3:18]:
| Disease | FGF2 Expression Change | Significance |
|---|---|---|
| Alzheimer's Disease | Increased (compensatory) | Correlation with disease severity |
| Parkinson's Disease | Increased | Associated with dopaminergic protection |
| ALS | Variable | May be insufficient for neuroprotection |
| Stroke | Increased | Response to injury |
Current research areas include[2:22][3:20][4:11][5:3][6:2]:
Various animal models have been used to study FGF2 in neurodegeneration[2:24][3:22][4:12]:
Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Woodbury ME, Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J Neuroimmune Pharmacol. 2014. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Reuss B, von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. 2003. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Goetz R, Mohammadi M. How FGFs bind to FGFRs. Nat Rev Mol Cell Biol. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Nakao Y, et al. Fibroblast growth factor-2 in Alzheimer's disease. Neuroscience. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Yoshimoto Y, et al. FGF-2 promotes dopaminergic neuron survival. Exp Neurol. 2005. ↩︎ ↩︎ ↩︎
Kwon YW, et al. Fibroblast growth factor-2 in motor neuron disease. Exp Neurol. 2007. ↩︎
Goebel J, et al. FGF-2 therapy for stroke. J Cereb Blood Flow Metab. 2018. ↩︎ ↩︎